Piper Jaffray Healthcare Conference In Brief
This article was originally published in The Gray Sheet
Executive Summary
J&J/DePuy ASR hip: Investigational device exemption filing for the Articular Surface Replacement less-invasive hip system will be submitted to FDA this year, leading to a U.S. launch in 2007, J&J Worldwide Chairman-Medical Devices & Diagnostics Michael Dormer reports at a Jan. 27 session of the Piper Jaffray Healthcare Conference in New York. A European debut is slated for this quarter. Targeting a $500 mil. market, the device "provides excellent function with less damage to the natural bone structure" and "permits total hip replacement in later years should the need ever arise," the exec explains. J&J also is readying the Proxima conservative hip replacement system, preparing to begin European trials by Q2 with hopes for a 510(k) submission by Q1 2005. Proxima is designed to support minimally-invasive surgical techniques. A ceramic-on-ceramic hip bearing already available outside the U.S. is on track for U.S. approval in the second half of 2004...
You may also be interested in...
S&N Preps For Potential Ceramic Hip Launch At March AAOS Meeting
Smith & Nephew expects PMA approval of a ceramic-on-ceramic hip by the second quarter of 2004, according to Orthopedics Division President David Illingworth
Abbott’s Lake County Plant Gets FDA Nod; Prism Squares Up For U.S. Debut
Abbott Labs will begin U.S. commercialization of its Prism, Architect and AxSYM full diagnostic assay menus over the next 12 months, following FDA's decision to end a four-year prohibition of product sales
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.